Curative Biotechnology, Inc. Announces Nomination of Dr. Jeffrey Liebmann to Board of Directors

Appointment of Independent Director to become effective upon approval by and listing of common stock on a National Exchange

Boca Raton, FL, Oct. 31, 2023 (GLOBE NEWSWIRE) — Curative Biotechnology Inc. (OTC: CUBT) (“Curative Biotech” or the “Company”), a development-stage biomedical company focused on novel treatments for degenerative eye diseases today announced its nomination to its Board of Directors of Dr. Jeffrey Liebmann. Dr. Liebmann is expected to join its Board of Directors as an independent director upon approval by and listing of the Company’s common stock on a National Exchange. In addition to other Board duties Dr. Liebmann would be expected to chair the newly created Clinical Development Committee of the Board.

Read more at globenewswire.com